Tag: Bisantrene

Race Oncology has released its Investor Presentation ahead of CEO Peter Molloy’s address at the BIO CEO Conference in New York City.

A key Bisantrene patent has received “Notice of Allowance” in the United States, which extends the commercial exclusivity period for the drug in the American market. The patent titled, “Combinatorial Methods to Improve the Therapeutic Benefit of Bisantrene and Analogs…

Race Oncology is pleased to announce the company has been invited to present at the ‘Biotech Showcase’ during the J.P. Morgan Healthcare Conference in San Francisco next week. Race Oncology Chief Executive Peter Molloy will present on Monday 8 January,…

In November 2017, Race CEO Peter Molloy spoke to investors in London at the Biotech & Money conference.